Pronounce: el-oh-TOOZ-ue-mab
Classification: monoclonal antibody
Monoclonal antibodies are created in a lab to attach to the targets found on specific types of cancer cells. The antibody “calls” the immune system to attack the cell it is attached to, resulting in the immune system killing the cell. These antibodies can work in different ways, including stimulating the immune system to kill the cell, blocking cell growth or other functions necessary for cell growth.
Elotuzumab works in two ways. It specifically targets the SLAMF7 (Signaling Lymphocytic Activation Molecule Family member 7) protein found on multiple myeloma cells. Elotuzumab attaches to the cells with the SLAMF7 protein, breaking them down. Elotuzumab also works by activating the body's immune system and enhances the ability of natural killer (NK) cells to attack the cancer cells.
Elotuzumab is administered intravenously (IV, directly into a vein). The dose is based on your height and weight. How often you receive the medication is based on which cycle you are in. The medication is given until the disease progresses or intolerance of side effects.
Patients are given pre-medications including dexamethasone (steroid), diphenhydramine (Benadryl), ranitidine, and acetaminophen (Tylenol) to help prevent or lessen the side effects of an infusion reaction. It is important to follow the directions on how to take the pre-medications. You may be required to take dexamethasone up to 24 hours prior to your dose of elotuzumab.
There are a number of things you can do to manage the side effects of elotuzumab. Talk to your care team about these recommendations. They can help you decide what will work best for you. These are some of the most common or important side effects:
White blood cells (WBC) are important for fighting infection. While receiving treatment, your WBC count can drop, putting you at a higher risk of getting an infection. This medication can suppress your immune system, putting you at higher risk of getting an infection whether or not your WBC count is low.
You should let your doctor or nurse know right away if you have a fever (temperature greater than 38°C or 100.4°F), sore throat or cold, shortness of breath, cough, burning with urination, or a sore that doesn't heal. Infections are a common side effect of treatment with elotuzumab. Some of the most common infections include upper respiratory tract infection, nasopharyngitis (common cold), cough, and pneumonia.
Tips to preventing infection:
Your red blood cells are responsible for carrying oxygen to the tissues in your body. When the red cell count is low, you may feel tired or weak. You should let your oncology care team know if you experience any shortness of breath, difficulty breathing, or pain in your chest. If the count gets too low, you may receive a blood transfusion.
Platelets help your blood clot, so when the count is low you are at a higher risk of bleeding. Let your oncology care team know if you have any excess bruising or bleeding, including nose bleeds, bleeding gums or blood in your urine or stool. If the platelet count becomes too low, you may receive a transfusion of platelets.
Fatigue is very common during cancer treatment and is an overwhelming feeling of exhaustion that is not usually relieved by rest. While on cancer treatment, and for a period after, you may need to adjust your schedule to manage fatigue. Plan times to rest during the day and conserve energy for more important activities. Exercise can help combat fatigue; a simple daily walk with a friend can help. Talk to your healthcare team for helpful tips on dealing with this side effect.
This medication can cause elevated blood sugar levels in patients with and without diabetes. Your oncology care team will monitor your blood sugar. If you develop increased thirst, urination or hunger, blurry vision, headaches or your breath smells like fruit, notify your healthcare team. Diabetics should monitor their blood sugar closely and report elevations to the healthcare team.
Your oncology care team can recommend medications to relieve diarrhea. Also, try eating low-fiber, bland foods, such as white rice and boiled or baked chicken. Avoid raw fruits, vegetables, whole grain breads, cereals, and seeds. Soluble fiber is found in some foods and absorbs fluid, which can help relieve diarrhea. Foods high in soluble fiber include: applesauce, bananas (ripe), canned fruit, orange sections, boiled potatoes, white rice, products made with white flour, oatmeal, cream of rice, cream of wheat, and farina. Drink 8-10 glasses of non-alcoholic, un-caffeinated fluid a day to prevent dehydration.
There are several things you can do to prevent or relieve constipation. Include fiber in your diet (fruits and vegetables), drink 8-10 glasses of non-alcoholic fluids a day, and keep active. A stool softener once or twice a day may prevent constipation. If you do not have a bowel movement for 2-3 days, you should contact your healthcare team for suggestions to relieve the constipation.
This medication can cause liver toxicity, which your oncology care team may monitor for using blood tests called liver function tests. Notify your healthcare provider if you notice yellowing of the skin or eyes, your urine appears dark or brown, or you have pain in your abdomen, as these can be signs of liver toxicity.
Peripheral neuropathy is a toxicity that affects the nerves. It causes numbness or a tingling feeling in the hands and/or feet, often in the pattern of a stocking or glove. This can get progressively worse with additional doses of the medication. In some people, the symptoms slowly resolve after the medication is stopped, but for some it never goes away completely. You should let oncology care team know if you experience numbness or tingling in the hands and/or feet, as they may need to adjust the doses of your medication.
Nutrition is an important part of your care. Cancer treatment can affect your appetite and, in some cases, the side effects of treatment can make eating difficult. Ask your oncology care team about nutritional counseling services at your treatment center to help with food choices.
Although there are no specific recommendations regarding pregnancy while taking elotuzumab, it is required that patients follow the REMS program if they are receiving lenalidomide or pomalidomide in combination with elotuzumab. Lenalidomide and pomalidomide can cause life-threatening birth defects. You should not become pregnant or father a child while taking either of these medications. For more information please see the medication sheets for lenalidomide and pomalidomide.
OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem or have questions or concerns about the medication that you have been prescribed, you should consult your health care provider.
Information Provided By: www.oncolink.org | © 2025 Trustees of The University of Pennsylvania